[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552009":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":31,"centralContacts":40,"locations":46,"responsibleParty":64,"collaborators":12,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":12,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":12,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":12,"overallStatus":49,"whyStopped":12,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Zunyi Medical College","OTHER",[8,13,19],{"label":9,"type":10,"description":11,"interventionNames":12},"blank control group","NO_INTERVENTION","In the blank control group, no intervention was used during the operation, and normal saline was pumped according to the participant's body weight until the end of the operation.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Low dose esketamine hydrochloride injection group","EXPERIMENTAL","In the low-dose ESketamine hydrochloride injection group, 50mg of Esketamine hydrochloride injection was diluted with normal saline into a 50ml syringe, which was wrapped with light-proof paper and pumped continuously from the beginning of anesthesia to the end of surgery. The dosage was calculated as 0.2mg\u002Fkg.h.",[18],"Drug: Esketamine hydrochloride injection",{"label":20,"type":15,"description":21,"interventionNames":22},"High dose esketamine hydrochloride injection group","In the high-dose ESketamine hydrochloride injection group, 50mg of Esketamine hydrochloride injection was diluted with normal saline into a 50ml syringe, which was wrapped with light-resistant paper and pumped continuously from the beginning of anesthesia to the end of surgery. Dosage was calculated as 0.4mg\u002Fkg.h.",[18],[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Esketamine hydrochloride injection","The low dose esketamine hydrochloride group was given 0.2mg\u002Fkg at induction of anesthesia, the high dose esketamine hydrochloride group was given 0.4mg\u002Fkg at induction of anesthesia, and the blank control group was not given Esketamine hydrochloride injection at induction of anesthesia.",[20,14],[30],"0.9% sodium chloride injection",[32,36],{"name":33,"affiliation":34,"role":35},"Wei Chen","Staff member of Department of Anesthesiology, Affiliated Hospital of Zunyi Medical University","STUDY_DIRECTOR",{"name":37,"affiliation":38,"role":39},"Haiying Wang","Director of anesthesiology Department, Affiliated Hospital of Zunyi Medical University","PRINCIPAL_INVESTIGATOR",[41],{"name":42,"role":43,"phone":44,"phoneExt":12,"email":45},"Xiaomei Zhang","CONTACT","+0086 18786233321","3233598996@qq.com",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Affiliated Hospital of Zunyi Medical University","RECRUITING","Zunyi","Guizhou","563000","China","CN",{"type":56,"coordinates":57},"Point",[58,59],106.90722,27.68667,{"lat":59,"lon":58},[62],{"name":42,"role":43,"phone":63,"phoneExt":12,"email":45},"+008618786233321",{"type":65,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"SPONSOR_INVESTIGATOR","Zhang XIao Mei","Anesthesiology resident, Affiliated Hospital of Zunyi Medical University","100552009","phase-4-to-investigate-the-effect-of-esketamine-hydrochloride-on-pulmonary-complications-100552009",false,"NCT06467513","To Investigate the Effect of Esketamine Hydrochloride on Pulmonary Complications","To Investigate the Effect of Esketamine on Hemodynamics and Postoperative Pulmonary Complications in Patients Undergoing Heart Valve Replacement Surgery","Inclusion Criteria:\n\n* Age 18-75 years old, gender unlimited.\n* Elective heart surgery.\n* Patients who plan to undergo mitral and (or) aortic valve replacement (or repair) surgery, requiring extracorporeal circulation and aortic occlusion.\n* The New York Heart Association class is less than 4.\n* Voluntarily sign informed consent.\n\nExclusion Criteria:\n\n* Non-cardiac surgery.\n* Second heart surgery.\n* Interventional surgery in heart valve surgery (TAVI, mitral clamp).\n* The patient refuses.\n* Pregnant women.\n* Patients with a history of lung surgery.\n* Patients with acute kidney injury requiring dialysis.\n* Patients with chronic renal insufficiency (stage III and above).\n* The patient was intubated before arriving at the operating room.\n* Patients with existing pulmonary complications (respiratory tract infection, pneumonia, pleural effusion, respiratory failure, atelectasis, pneumothorax, bronchospasm, ARDS).\n* The patient had neuropsychiatric disease and cognitive impairment before surgery.\n* Drug users and other long-term use of antipsychotic drugs.\n* Patients with any of the following contraindications for the use of ESketamine injection: patients with serious risk of elevated blood pressure or intracranial pressure; Patients with high intraocular pressure (glaucoma) or penetrating ocular trauma; Patients with poorly controlled or untreated hypertension (arterial hypertension, resting systolic pressure exceeding 180 mmHg, or resting diastolic pressure exceeding 100mmHg); Patients with untreated or undertreated hyperthyroidism (hyperthyroidism).\n* Liver function ALT, AST \\> 2 times normal.","ALL","18 Years","75 Years",{"count":79,"type":80},102,"ESTIMATED","INTERVENTIONAL",[83],"PHASE4","The objective of this study was to evaluate the effect of esketamine on intraoperative hemodynamics in patients with heart valve replacement and to mitigate postoperative pulmonary complications",[86,87],"Heart Diseases","Heart Valve Diseases","2024-06-14",{"date":90,"type":91},"2024-06-21","ACTUAL",{"date":93,"type":91},"2024-01-01",{"date":95,"type":80},"2025-05",{"name":66,"class":6},1]